Advanced Search

 

Study ID Status Title Patient Level Data
PAR03_001 Completed A Double-Blind, Imipramine- and Placebo-Controlled Study of Paroxetine in Depressed Outpatients Study Listed on ClinicalStudyDataRequest.com
PC 90-01 Completed Pharmacokinetics and Safety of Lamotrigine in Young Epileptic Children
PCR103124 Completed A Multicentre, Double-blind, Active Controlled Trial to Evaluate the Clinical Effects of Immediate Release Paroxetine and Controlled Release Paroxetine in the Treatment of Major Depression
PCR104074 Completed A randomized, open, three-period crossover study to compare the pharmacokinetic profile of paroxetine after single dosing of each enteric-coated Geomatrix control release tablet strength (12.5, 25, 37.5mg) in healthy Chinese subjects
PCR104075 Completed A steady-state study to assess the pharmacokinetic profile of paroxetine after 14 day repeated daily dosing of the controlled release paroxetine tablet (25 mg) in healthy Chinese subjects
PCR111656 Completed An open-label, randomized, single dose, two-period crossover study to demonstrate bioequivalence between the controlled release paroxetine tablet (37.5 mg) manufactured at Cidra and Mississauga Study Listed on ClinicalStudyDataRequest.com
PGA105446 Completed Clinical Evaluation of 506U78 in Japanese Patients with Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.
PGAA1001 Completed A phase I study of 2-amino-9-b-D-arabinofuranosyl-6-methoxy-9H-purine (Compound 506) in children and adults with refractory hematologic malignancies.
PGAA1002 Completed A phase I study of 506U78 administered as a two hour infusion daily for 3 consecutive days in adult patients and as a two hour infusion daily over 5 consecutive days in pediatric patients with refractory hematologic malignancies.
PGAA1003 Completed Phase I study of 506U78 administered as a two hour infusion on a day 1, 3, and 5 schedule in patients with refractory hematologic malignancies.
PGAA1005 Completed Pilot study of pharmacodynamic investigation of treatment with 506U78 combined with fludarabine in refractory leukemics.
PGAA2001 Completed A Phase II Study of 506U78 in Patients with Refractory T-Cell Malignancies – CCG Intergroup Study
PGAA2003 Completed A Multicenter Study to Assess the Efficacy of 506U78 in Subjects with Chronic Lymphocytic Leukemia (CLL) who are Refractory to Fludarabine and Alkylator Therapy
PHX111427 Completed A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects
PIK111051 Terminated A Phase I Open-Label, Dose-Escalation Study of the Phosphoinositide 3-Kinase Inhibitor GSK1059615 in Patients with Solid Tumors or Lymphoma Study Listed on ClinicalStudyDataRequest.com
PIR104776 Completed Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) A Double-blind, Placebo-controlled Study
PIR104777 Completed Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study-
PIR109164 Terminated Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) - A Placebo-controlled, Single-Blind Comparative Study - Study Listed on ClinicalStudyDataRequest.com
PKI108574 Terminated A randomized, double blind, placebo controlled study to explore the antidepressant properties of P38a Kinase inhibitor GW856553X 15mg compared to PBO in Subjects with Major Depressive Disorder exhibiting symptoms of loss of energy and interest and psychomotor retardation, for a six week treatment period Study Listed on ClinicalStudyDataRequest.com
PKM5053 Completed A repeated dose study to assess the pharmacokinetic profiles and the safety of Org31540/SR90107A by subcutaneous administration of 0.75, 1.5, 2.5, and 3.0mg to Japanese healthy elderly subjects
PLK107427 Completed A Phase I Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of [GSK461364], a Polo-like Kinase 1 (PLK1) Inhibitor, in Adult Subjects with Advanced Solid Tumor or Non-Hodgkins Lymphoma Study Listed on ClinicalStudyDataRequest.com
PM1111138 Completed A double-blind, placebo-controlled, parallel group study to evaluate the effects of two regimens of GW856553, over a period of 3 month, on in-vivo macrophage activity, as assessed by FDG-PET/CT imaging, in the carotid arteries and aorta of subjects with established atherosclerosis Study Listed on ClinicalStudyDataRequest.com
PMK103351 Completed A 28-day, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, anti-inflammatory effect and steady-state pharmacokinetics of SB-681323 (7.5 mg) in subjects with coronary heart disease (CHD) undergoing elective percutaneous coronary interventions (PCI)
POP5108 Completed A repeated dose pharmacokinetic study in healthy volunteers to compare 1.5 mg of fondaparinux sodium in subjects with a low (35 to 50 kg) body weight (LBW) to 2.5 mg of fondaparinux sodium in subjects with standard (60 to 100 kg) body weight (SBW)
PREV123 Completed Multicentre randomised trial comparing two strategies for the episodic use of valaciclovir, alone or combined with suppressive treatment in immunocompetent patients with recurrent genital herpes

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.